Aims-To estimate the proportion and nature of the proliferating (Ki67+) circulating lymphocytes in a series ofpatients with multiple myeloma and monoclonal gammopathy of unknown significance (MGUS) and to correlate this with other clinical and laboratory parameters, using blood from healthy adults as a control. To investigate the extent to which the B and
Multiple myeloma is a B cell disorder characterised by the clonal proliferation of B cells at late stages of lymphoid differentiation and has distinct clinical features such as the presence of a serum monoclonal band, variable degree of bone marrow infiltration by plasma cells and osteolytic bone lesions. The clinical course in multiple myeloma varies remarkably from aggressive to slowly progressive or even stable.'2 Benign monoclonal gammopathy of undetermined significance (MGUS) is closely related to multiple myeloma, and is regarded by many authors as a premalignant condition, gradually evolving into multiple myeloma in 10-20% of patients. 34 A number of clinical and laboratory features are regarded as prognostic factors in multiple myeloma. These include age, sex, immunoglobulin subclass, haemoglobin, serum calcium, lactate dehydrogenase (LDH), creatinine, f-2-microglobulin, plasma cell morphology, and clinical stage.5-9 Other laboratory parameters, such as T cell subset, expression ofnatural killer and activation markers in blood lymphocytes,'01' the multidrug resistance glycoprotein P-170 (MDR-1), and CD56 on plasma cells, are also of prognostic relevance and may be of value in distinguishing between MGUS and multiple myeloma. '2 One of the prognostic factors in multiple myeloma is related to the degree of plasma cell proliferation. The plasma cell labelling index (PCLI), measured using either [3H] thymidine or 5-bromo-2-deoxyuridine uptake, has been used to estimate proliferation in multiple myeloma and has been shown to be a useful parameter for distinguishing between progressive multiple myeloma and stable MGUS as well as being an independent predictor of survival.9"'1' Similarly, Lokhorst et al'6 investigated the expression ofKi67, a monoclonal antibody which detects cells in cycle,'718 and demonstrated that the percentage of Ki67 + plasma cells in MGUS is significantly lower than that in untreated multiple myeloma.
Miguel-Garcia, Matutes, Tanin, Garcia-Talavera, Miguel-Sosa, Carbonell, et al In an earlier study '9 we showed that the percentage of circulating Ki67 + clonal B cells in chronic lymphocytic leukaemia is related to disease progression and that in the early stages of this disease the proliferating cells are mainly reactive T cells. This prompted us to investigate, using a double immunoenzymatic staining technique, Ki67 expression in circulating lymphocytes from patients with multiple myeloma and MGUS to estimate the extent to which the B and T cells modulate disease progression and whether Ki67 expression can used to distinguish between these two conditions. Results A small number of lymphocytes from patients with multiple myeloma and MGUS and from controls were Ki67 + (table 1). The proportion of Ki67 + cells was significantly higher in multiple myeloma and MGUS compared with the normal samples and was higher in multiple myeloma than in MGUS. Analysis of the expression of lymphoid markers within the Ki67 + cell population showed that over half of Ki67 + cells were CD3 + in all three groups (fig 1) .Thus, most of the Ki67 + cells were T lymphocytes; only a minority expressed the immunoglobulin K and k light chains (B cells) (table 1). There were no significant differences in the proportion of CD3 + Ki67 + cells among the three groups, whereas the proportion of Ki67 + B lymphocytes (K or X positive) in patients with multiple myeloma and MGUS was significantly lower than that in normal controls (table 1) .
Methods
In all cases, Ki67/K and Ki67/k double stained lymphocytes were observed (non-clonal B lymphocytes). HLA-Dr determinants were expressed in a high proportion of cells in cycle in all cases (table 1) (fig 2) . Although triple labelling analysis with Ki67, HIA-Dr and CD3
was not performed, the data shown here, when the percentage of Ki67 + cells coexpressing CD3 and immunoglobulins is taken into consideration, suggest that a significant proportion of proliferating T cells (CD3 + Ki67 +) were activated T lymphocytes (HLA-Dr +) (table 1).
Ki67 positive lymphocytes in myeloma and MGUS Figure 1 Lymphocytes from a patient with multiple myeloma, four of which were CD3 + (red stained cytoplasm (APAAP)). One was also Ki67+ as indicated by the brown stained nucleus.
Differences between multiple myeloma, MGUS and control samples became apparent when the two T cell subsets, CD4 + and CD8 +, were considered separately (table 2). In multiple myeloma the proportion of CD4 + T cells in cycle was significantly lower than that in the controls whereas the numbers of CD8 + Ki67 + cells were higher in multiple myeloma and MGUS samples, as was expression of CDl lb in Ki67 + cells (table 2) .
Statistical analysis revealed a positive correlation between the percentage of Ki67 + cells and clinical stage and 3-2-microglobulin concentrations (r=0-6) ( figs 3 and 4) . No correlation was found between the percentage of Ki67 + cells and the other parameters studied. Figure 2 Lymphocytes from a patient with MGUS, one of which was both Ki67+ (brown stained nucleus) and HLADr+ (red stained cytoplasm (APAAP)). Lc factors are also of use when determining higher in patients with multiple myeloma than ype of treatment to be instituted (intensive in those with MGUS or in normal controls, iotherapy and autologous and allogenic and that the proliferating (Ki67 +) cells in marrow transplantation versus standard multiple myeloma are mainly suppressor T iotherapy) because of the morbidity and (CD8 +) cells, some of which also express -ality associated with some procedures.13 activation antigens (HLA-Dr) and CDl lb. In the various prognostic factors, deter-multiple myeloma, only a small number of B tion of the PCLI, either by uptake of lymphocytes are in cycle and are not generated thymidine or bromodeoxyuridine,9 15 or by solely by the neoplastic clone. Assessment of expression,'622 has been shown to be Ki67 expression in peripheral blood lymLdependent prognostic indicator of disease phocytes might constitute a good prognostic ression and can be used to distinguish indicator of disease activity in multiple my-,een MGUS and multiple myeloma. eloma given the positive correlation between e have analysed the degree of proliferation the proportion ofKi67 ± lymphocytes and conrculating blood lymphocytes from patients centrations of [-2-microglobulin and disease multiple myeloma and MGUS and com-stage. In turn this could be used to distinguish d this with normal controls to determine between multiple myeloma and MGUS. Seher this can be used as a prognostic quential studies in MGUS may predict whether :ator. Our findings demonstrate that, in a particular subgroup of patients is at greater -iple myeloma and MGUS, only a small risk of developing multiple myeloma. 
